Crystallization (Comment) | Organism |
---|---|
molecular docking studies of inhibitor 2-(N-benzoxycarbonyl)aminoethyl-N-(4-hydroxyamino-4-oxo-2-(isopropylthio)butanoyl)-L-3-phenylalanyl-L-alanyl amide | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
N-[4-(hydroxyamino)-4-oxo-2-(phenylsulfanyl)butyl]-3-(naphthalen-2-yl)-L-alanyl-N-(2-{[(benzyloxy)carbonyl]amino}ethyl)-L-alaninamide | peptidomimetic inhibitor, 54.5% inhibition in in vitro lipopolysaccharide cytotoxicity tests, inhibitory activity in vivo by measuring the expression of mTNFalpha | Homo sapiens | |
N-[4-(hydroxyamino)-4-oxo-2-(phenylsulfanyl)butyl]-L-phenylalanyl-N-(2-{[(benzyloxy)carbonyl]amino}ethyl)-L-alaninamide | peptidomimetic inhibitor, 54.5% inhibition in in vitro lipopolysaccharide cytotoxicity tests | Homo sapiens | |
N-[4-(hydroxyamino)-4-oxo-2-(propan-2-ylsulfanyl)butyl]-L-phenylalanyl-N-(2-{[(benzyloxy)carbonyl]amino}ethyl)-L-alaninamide | peptidomimetic inhibitor, 27.3% inhibition in in vitro lipopolysaccharide cytotoxicity tests, molecular docking studies | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
HL-60 cell | - |
Homo sapiens | - |